


substituted heteroaryloxy, optionally substituted heteroaralkyloxy, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, halo, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, carboxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, acylamino, and sulfonylamino; or

5 R^4 and R^5 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocycloamino ring; or

a pharmaceutically acceptable salt thereof.

In another aspect, provided herein is a compound having the structure:



10 or


a pharmaceutically acceptable salt thereof.

In another aspect, provided herein is a pharmaceutical composition comprising a compound as described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

15 In another aspect, provided is a use of the pharmaceutical composition as described herein in the manufacture of a medicament for treating a disease treatable by inhibiting NF- κ B activation.

What is Claimed:

1. A compound of Formula (IB):



(IB)

5

wherein:

n is 0, 1, or 2;

Het is heteroaryl optionally substituted with R^a, R^b, and/or R^c independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl;

10

R¹ is hydrogen or alkyl;

R² is hydrogen or alkyl;

R³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthioalkyl, aminoalkyl, acylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl,

15

aminocarbonylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, wherein aryl or heteroaryl by itself as part of aralkyl or heteroaralkyl is optionally substituted with R^d, R^e, and/or R^f independently selected from alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro, carboxy, alkoxycarbonyl, amino, alkylamino, and dialkylamino;

R⁴ is hydrogen or alkyl; and

20

R⁵ is -C(O)R⁶ where R⁶ is alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl wherein aryl or heteroaryl by itself or as part of aralkyl or heteroaralkyl is optionally substituted with R^g, R^h, and/or Rⁱ independently selected from alkyl, alkoxy, aminoalkoxy, hydroxyalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted heteroaryloxy, optionally substituted heteroaralkyloxy, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, halo, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, carboxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, acylamino, and sulfonylamino; or

25


R⁴ and R⁵ together with the nitrogen atom to which they are attached form a 5 to 7

30

membered heterocycloamino ring; or

a pharmaceutically acceptable salt thereof.

2. A compound having the structure:



- 5 or
a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein n is 1 or 2.

- 10 4. The compound of claim 1 or claim 3 wherein n is 1.

5. The compound of claim 1 wherein n is 0 or 2.

6. The compound of claim 1 wherein n is 0.

15

7. The compound of claim 1 wherein n is 2.

8. The compound of any one of claims 1 and 3 to 7 wherein R^4 is hydrogen or alkyl and R^5 , where present, is $-C(O)R^6$ where R^6 is alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, or heterocycloalkyl wherein aryl or heteroaryl by itself or as part of aralkyl or heteroaralkyl are optionally substituted with R^g , R^h , and/or R^i independently selected from alkyl, alkoxy, aminoalkoxy, hydroxyalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, optionally substituted aralkyloxy, optionally substituted heteroaryloxy, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, halo, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, carboxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, acylamino, and sulfonylamino.

9. The compound of claim 8 wherein R^6 is aryl or heteroaryl optionally substituted with R^g , R^h , and/or R^i .

30

10. The compound of claim 8 wherein R⁶ is aralkyl or heteroaralkyl optionally substituted with R^g, R^h, and/or Rⁱ.
- 5 11. The compound of claim 8 wherein R⁶ is phenyl optionally substituted with R^g, R^h, and/or Rⁱ.
- 10 12. The compound of any one of claims 1 and 3 to 11 wherein R^g is alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, or cyano and R^h and Rⁱ are independently selected from alkyl, alkoxy, aminoalkoxy, hydroxyalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, optionally substituted aralkyloxy, optionally substituted heteroaryloxy, optionally substituted heterocycloalkyloxy, optionally substituted heterocycloalkylalkyloxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, carboxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, acylamino, or sulfonylamino.
- 15 13. The compound of any one of claims 1 and 3 to 11 wherein R^g, R^h and Rⁱ are independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, acylamino, preferably, methyl, ethyl, methoxy, ethoxy, chloro, fluoro, trifluoromethyl, trifluoromethoxy, hydroxy, acetylamino, butanoylamino, and pentanoylamino.
- 20 14. The compound of any one of claims 1 and 3 to 7 wherein R⁴ and R⁵ together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocycloamino ring.
- 25 15. The compound of any one of claims 1 and 3 to 14 wherein R¹ and R² are independently hydrogen or methyl, preferably hydrogen.
16. The compound of any one of claims 1 and 3 to 15 wherein when both R¹ and R² are alkyl, they are not bound to the same ring carbon.
- 30 17. The compound of any one of claims 1 and 3 to 16 wherein Het is pyridinyl, pyrimidinyl, pyrazinyl, furanyl, thienyl, quinolinyl, isoquinolinyl, pyrazolyl, or indolyl, each ring optionally substituted with R^a, R^b, and R^c independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, dialkylamino, carboxy, and alkoxycarbonyl.

18. The compound of any one of claims 1 and 3 to 16 wherein R^a, R^b, and R^c independently selected from methyl, ethyl, methoxy, ethoxy, chloro, fluoro, trifluoromethyl, trifluoromethoxy, cyano, amino, methylamino, or dimethylamino.
- 5 19. The compound of any one of claims 1 and 3 to 16 wherein Het is pyridin-3-yl.
20. The compound of any one of claims 1 and 3 to 19 wherein R³ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthioalkyl, aminoalkyl, acylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, aryl, aralkyl, heteroaryl, 10 or heteroaralkyl wherein aryl or heteroaryl by itself or in aralkyl and heteroaralkyl is optionally substituted with R^d, R^e, and/or R^f independently selected from alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro, carboxy, alkoxycarbonyl, amino, alkylamino, and dialkylamino.
- 15 21. The compound of any one of claims 1 and 3 to 19 wherein R³ is hydrogen or alkyl, preferably methyl, ethyl, propyl, isopropyl, sec-propyl, n-, sec, iso, tert-butyl.
22. The compound of any one of claims 1 and 3 to 19 wherein R³ is aralkyl optionally substituted with R^d, R^e, and/or R^f, preferably R³ is benzyl or phenethyl, more preferably benzyl 20 optionally substituted with R^d, R^e, and/or R^f, even more preferably R³ is benzyl.
23. The compound of any one of claims 1 and 3 to 19 wherein R³ is cycloalkylalkyl optionally substituted with R^d, R^e, and/or R^f, preferably R³ is cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, or cyclohexylmethyl optionally substituted with R^d, R^e, and/or R^f. 25
24. The compound of any one of claims 1 and 3 to 19 wherein R³ is heteroaralkyl (e.g., thienylmethyl, furanylmethyl, pyridinylmethyl, quinolinylmethyl, isoquinolinylmethyl, indolylmethyl, or indazolylmethyl) optionally substituted with R^d, R^e, and/or R^f.
- 30 25. The compound of any one of claims 1 and 3 to 19 wherein R³ is hydroxyalkyl, alkoxyalkyl, aminoalkyl, preferably R³ is hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, aminomethyl, or aminobutyl.

26. The compound of any one of claims 1 and 3 to 25 wherein the stereochemistry at carbon to which R³ is attached is (S).
27. The compound of any one of claims 1 and 3 to 25 wherein the stereochemistry at carbon to
5 which R³ is attached is (R).
28. A pharmaceutical composition comprising a compound of any one of claims 1-27 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
- 10 29. Use of the pharmaceutical composition of claim 28 in the manufacture of a medicament for treating a disease treatable by inhibiting NF-kB activation.
30. The use of claim 29 wherein the disease is an inflammatory disease.
- 15 31. The use of claim 30 wherein the disease is selected from the group consisting of autoimmune disease, pain, allergies, asthma, chronic obstructive pulmonary disease and sepsis.
32. The use of claim 29 wherein the disease is selected from the group consisting of
rheumatoid arthritis, osteoarthritis, atherosclerosis, multiple sclerosis, asthma, inflammatory
20 bowel disease, diabetes, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, osteoporosis, systemic lupus erythematosus, chronic obstructive pulmonary disease, cystic fibrosis, stroke, acute kidney injury, glomerulonephritis, psoriasis, atopic dermatitis, Behcet's disease, tuberculosis, Crohn's disease, colitis, Pagett's disease, pancreatitis, periodontitis, inflammatory lung disease, and lupus nephritis.
- 25 33. The pharmaceutical composition of claim 28 for use as a medicament.